SCHEMBL1338640

SCHEMBL1338640

Cc1cnc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ F2RL3 Q96RI0 1/20 0.38
▸ CNR1 P21554 6/20 0.37
▸ CNR2 P34972 6/20 0.37
▸ HSD11B1 P28845 3/20 0.37
▸ TNKS O95271 1/20 0.35
▸ STK4 Q13043 1/20 0.35
▸ STK3 Q13188 1/20 0.35
▸ SIK2 Q9H0K1 1/20 0.35
▸ STK26 Q9P289 1/20 0.35
▸ STK24 Q9Y6E0 1/20 0.35
▸ GABRA1 P14867 4/20 0.34
▸ GABRG2 P18507 3/20 0.34
▸ GABRB3 P28472 3/20 0.34
▸ GABRA5 P31644 3/20 0.34
▸ RIPK2 O43353 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3574329 0.85 HSD17B10 (0.42) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1336869 0.85 KDM4E (0.39) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1338764 0.83 BRD4 (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL3577543 0.83 KDM4E (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339468 0.83 KDM4E (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339351 0.81 F2RL3 (0.38) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1380418 0.80 KDM4E (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1338386 0.80 NOTUM (0.45) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1339274 0.80 KDM4E (0.40) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1338174 0.80 CSF1R (0.38) KDM4EALDH1A1GAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 KDM4E 1908/4885ALDH1A1 283/4885GAA 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback